The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer

• Published in: Journal of lipid research Vol. 62; p. 100130
• Main Author: Seidah, Nabil G.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2021; American Society for Biochemistry and Molecular Biology; Elsevier
• Subjects: Animals; cancer/metastasis; furin; Humans; hypercholesterolemia; Hypercholesterolemia - enzymology; inflammation; LDL-C; LDLR; lipid metabolism; lysosomes; Neoplasms - enzymology; Proprotein Convertase 9 - metabolism; proprotein convertases; Thematic Review Series; viral infection; Virus Diseases - enzymology; FH; viral infection; LDL-C; lipid metabolism; CHRD; MHC; PCSK9; hypercholesterolemia; HEK293; S1P; inflammation; cancer/metastasis; DENV; lysosomes; cDNA; NARC-1; LDLR; GOF; SKI-1; LOF; proprotein convertases; ER; mAb; PC; furin
• ISSN: 0022-2275; 1539-7262
• DOI: 10.1016/j.jlr.2021.100130

In 2003, the sequences of mammalian proprotein convertase subtilisin/kexin type 9 (PCSK9) were reported. Radiolabeling pulse-chase analyses demonstrated that PCSK9 was synthesized as a precursor (proPCSK9) that undergoes autocatalytic cleavage in the endoplasmic reticulum into PCSK9, which is then secreted as an inactive enzyme in complex with its inhibitory prodomain. Its high mRNA expression in liver hepatocytes and its gene localization on chromosome 1p32, a third locus associated with familial hypercholesterolemia, other than LDLR or APOB, led us to identify three patient families expressing the PCSK9 variants S127R or F216L. Although Pcsk9 and Ldlr were downregulated in mice that were fed a cholesterol-rich diet, PCSK9 overexpression led to the degradation of the LDLR. This led to the demonstration that gain-of-function and loss-of-function variations in PCSK9 modulate its bioactivity, whereby PCSK9 binds the LDLR in a nonenzymatic fashion to induce its degradation in endosomes/lysosomes. PCSK9 was also shown to play major roles in targeting other receptors for degradation, thereby regulating various processes, including hypercholesterolemia and associated atherosclerosis, vascular inflammation, viral infections, and immune checkpoint regulation in cancer. Injectable PCSK9 monoclonal antibody or siRNA is currently used in clinics worldwide to treat hypercholesterolemia and could be combined with current therapies in cancer/metastasis. In this review, we present the critical information that led to the discovery of PCSK9 and its implication in LDL-C metabolism. We further analyze the underlying functional mechanism(s) in the regulation of LDL-C, as well as the evolving novel roles of PCSK9 in both health and disease states.